



IMPORTANT SUPPLY UPDATE

Good news about TOPROL-XL and metoprolol succinate extended-release tablets!

TOPROL-XL— Trusted for 24-hour treatment



June 2009

SUPPLY UPDATE: TOPROL-XL and generic metoprolol succinate extended-release tablets—all strengths available

Wilmington, Delaware—A significant quantity of once-daily TOPROL-XL and its generic equivalent, metoprolol succinate extended-release tablets, has been delivered to retail pharmacies throughout the United States. Patients should now be able to get their prescription for TOPROL-XL or metoprolol succinate filled at their pharmacies in all 4 strengths: 25 mg, 50 mg, 100 mg, and 200 mg.

Patients taking TOPROL-XL or metoprolol succinate should avoid abrupt cessation of their medication.

Available to meet market demand

TOPROL-XL (metoprolol succinate) Extended-Release Tablets Ordering Information¹

NDC#	Product Description	Count	For more information, please ask your AstraZeneca representative, call toll-free, 1-800-236-9933, or visit TOPROL-XL.com
00186-1088-05	25 mg tablets	100	
00186-1090-05	50 mg tablets	100	
00186-1092-05	100 mg tablets	100	
00186-1094-05	200 mg tablets	100	

Metoprolol Succinate Extended-Release Tablets* Ordering Information² (generic equivalent of TOPROL-XL)

NDC#	Product Description	Count	For more information, please ask your Par representative, call toll-free, 1-800-828-9393, or visit www.parpharm.com
49884-404-01	25 mg tablets	100	
49884-404-10	25 mg tablets	1000	
49884-405-01	50 mg tablets	100	
49884-405-10	50 mg tablets	1000	
49884-406-01	100 mg tablets	100	
49884-406-10	100 mg tablets	1000	
49884-407-01	200 mg tablets	100	
49884-407-10	200 mg tablets	1000	

*Manufactured for Par Pharmaceutical Companies, Inc., Spring Valley, NY, by AstraZeneca AB, Södertälje, Sweden.

Important Safety Information about TOPROL-XL¹

- Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered TOPROL-XL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, TOPROL-XL administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or